STORRE
STORRE: Stirling Online Research Repository
Please use this identifier to cite or link to this item:
http://hdl.handle.net/1893/29475| Appears in Collections: | Faculty of Health Sciences and Sport Journal Articles |
| Peer Review Status: | Refereed |
| Title: | Evaluation of discharge prescriptions for secondary prevention in patients with acute coronary syndromes in Iraq |
| Author(s): | Nassr, Ola A Forsyth, Paul Johnson, Chris F |
| Keywords: | Acute Coronary Syndrome Professional Practice Guideline Adherence Drug Utilization Angiotensin-Converting Enzyme Inhibitors Angiotensin Receptor Antagonists Clinical Audit Iraq |
| Issue Date: | Mar-2019 |
| Date Deposited: | 10-May-2019 |
| Citation: | Nassr OA, Forsyth P & Johnson CF (2019) Evaluation of discharge prescriptions for secondary prevention in patients with acute coronary syndromes in Iraq. Pharmacy Practice, 17 (1), Art. No.: 1372. https://doi.org/10.18549/PharmPract.2019.1.1372 |
| Abstract: | Background: Optimal prescribing of secondary prevention medications after acute coronary syndrome (ACS) events has been shown to reduce morbidity and mortality. However, it is unknown whether these medications are optimally prescribed at discharge from acute care in Iraq. Objective: To evaluate whether patients with ACS received optimal secondary prevention medications: antiplatelets, statins, angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers (ACEI/ARBs), and beta-blockers at discharge from a cardiology unit, and to assess whether statins, ACEI/ARBs and beta-blockers were prescribed at target doses based on the American Heart Association/American College of Cardiology (AHA/ACC) guidelines. Methods: Observational retrospective cross-sectional study of patients with ACS admitted to a hospital in Baghdad and survived to discharge between May 2016 and January 2017. Patient-level data and secondary prevention medications at discharge were extracted from routine medical records. Optimal dosing was defined as ≥75%, moderate dosing as 50–74%, and low dosing as |
| DOI Link: | 10.18549/PharmPract.2019.1.1372 |
| Rights: | Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License (CC-BY-NC-ND - https://creativecommons.org/licenses/by-nc-nd/3.0/) that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal. |
| Licence URL(s): | http://creativecommons.org/licenses/by-nc-nd/3.0/ |
Files in This Item:
| File | Description | Size | Format | |
|---|---|---|---|---|
| Nassr-etal-PharmacyPractice-2019.pdf | Fulltext - Published Version | 795.31 kB | Adobe PDF | View/Open |
This item is protected by original copyright |
A file in this item is licensed under a Creative Commons License
Items in the Repository are protected by copyright, with all rights reserved, unless otherwise indicated.
The metadata of the records in the Repository are available under the CC0 public domain dedication: No Rights Reserved https://creativecommons.org/publicdomain/zero/1.0/
If you believe that any material held in STORRE infringes copyright, please contact library@stir.ac.uk providing details and we will remove the Work from public display in STORRE and investigate your claim.